Skip to main content
COR
NYSE Trade & Services

Cencora Reports Strong Q2 Earnings, Raises FY26 EPS Guidance, and Announces $1 Billion Share Repurchase

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Positive
Importance info
8
Price
$309
Mkt Cap
$59.507B
52W Low
$271
52W High
$377.54
52W Position info
14% above low
Off High info
18% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

COR is trading near its 52-week low of $271 (14% above the low).

Summary

Cencora reported strong Q2 fiscal 2026 earnings, raised its full-year adjusted diluted EPS guidance, and announced a $1 billion share repurchase program.


Key Events · Earnings and Guidance · COR

  • Strong Q2 Fiscal 2026 Financial Performance

    Revenue increased 3.8% year-over-year to $78.4 billion. Adjusted diluted EPS rose 7.5% to $4.75, while GAAP diluted EPS was $8.40, including a $1.1 billion gain related to the OneOncology acquisition.

  • Raised Fiscal Year 2026 Adjusted EPS Guidance

    The company updated its adjusted diluted EPS guidance for fiscal year 2026 to a range of $17.65 to $17.90, up from the previous range of $17.45 to $17.75.

  • Announced $1 Billion Share Repurchase Program

    Cencora expects to repurchase $1 billion in shares by the end of calendar 2026, indicating a significant capital return to shareholders.

  • Strategic Portfolio Adjustments

    The company announced a definitive agreement for MWI Animal Health to merge with Covetrus and the acquisition of EyeSouth Partners' retina business.


Analysis · COR · Trade & Services

Cencora delivered robust second-quarter fiscal 2026 results, exceeding expectations with a 7.5% increase in adjusted diluted EPS and a 3.8% rise in revenue. The company's decision to raise its full-year adjusted diluted EPS guidance signals strong confidence in its operational performance and future outlook. Furthermore, the announcement of a $1 billion share repurchase program by the end of calendar 2026 demonstrates a significant commitment to returning capital to shareholders, which is a material capital allocation decision for a company of this size. The financial impact of the OneOncology acquisition, including a substantial remeasurement gain, also contributed to the strong GAAP EPS.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, COR was trading at $309.00 on NYSE in the Trade & Services sector, with a market capitalization of approximately $59.5B. The 52-week trading range was $271.00 to $377.54. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

COR - Latest Insights

COR
Nov 13, 2026, 11:43 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $356.14
Real-time Price: $339.83 info
Change: -$16.31 (-5%) info
Market Cap: $64.931B info
COR
Nov 04, 2026, 9:25 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $345.75
Real-time Price: $339.83 info
Change: -$5.92 (-2%) info
Market Cap: $64.931B info
COR
Nov 04, 2026, 6:37 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $342.67
Real-time Price: $339.83 info
Change: -$2.84 (-0.83%) info
Market Cap: $64.931B info
COR
Nov 04, 2026, 6:35 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $343.67
Real-time Price: $339.83 info
Change: -$3.84 (-1%) info
Market Cap: $64.931B info
COR
Oct 21, 2026, 7:48 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $342.51
Real-time Price: $339.83 info
Change: -$2.68 (-0.78%) info
Market Cap: $64.931B info